Literature DB >> 3110284

Serologically defined V region subgroups of human lambda light chains.

A Solomon, D T Weiss.   

Abstract

The availability of numerous antisera prepared against lambda-type Bence Jones proteins and lambda chains of known amino acid sequence has led to the differentiation and classification of human lambda light chains into one of five V lambda subgroups. The five serologically defined subgroups, V lambda I, V lambda II, V lambda III, V lambda IV, and V lambda VI, correspond to the chemical classification that is based on sequence homologies in the first framework region (FR1). Proteins designated by sequence as lambda V react with specific anti-lambda II antisera and are thus included in the V lambda II subgroup classification. The isotypic nature of the five V lambda subgroups was evidenced through analyses of lambda-type light chains that were isolated from the IgG of normal individuals. Based on analyses of 116 Bence Jones proteins, the frequency of distribution of the lambda I, lambda II/V, lambda III, lambda IV, and lambda VI proteins in the normal lambda chain population is estimated to be 27%, 37%, 23%, 3%, and 10%, respectively. This distribution of V lambda subgroups was comparable to that found among 82 monoclonal Ig lambda proteins. Considerable V lambda intragroup antigenic heterogeneity was also apparent. At least two sub-subgroups were identified among each of the five major V lambda subgroups, implying the existence of multiple genes in the human V lambda genome. The V lambda classification of 54 Ig lambda proteins obtained from patients with primary or multiple myeloma-associated amyloidosis substantiated the preferential association of lambda VI light chains with amyloidosis AL and the predominance of the normally rare V lambda VI subgroup in this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110284

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Crystallization of a complex between the Fab fragment of a human immunoglobulin M (IgM) rheumatoid factor (RF-AN) and the Fc fragment of human IgG4.

Authors:  M K Sohi; A L Corper; T Wan; M Steinitz; R Jefferis; D Beale; M He; A Feinstein; B J Sutton; M J Taussig
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 3.  Structural and functional properties of human lambda-light-chain variable-region subgroups.

Authors:  A Solomon; D T Weiss
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

4.  Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies.

Authors:  A Solomon; D T Weiss; S D Macy; R A Antonucci
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

5.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

6.  Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease.

Authors:  C Decourt; G Touchard; J L Preud'homme; R Vidal; H Beaufils; M C Diemert; M Cogné
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.